中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (11): 795-798.doi: 10.12144/zgmfskin202411795

• 临床研究 • 上一篇    下一篇

依奇珠单抗治疗坏疽性脓皮病一例并文献复习

王天姿1,2,宋朋1,2,张铭凯1,2,陈明飞1,2,刘永霞1,2,杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-11-15 发布日期:2024-10-14

Pyoderma gangrenosum successfully treated with ixekizumab: a case report and literature review

WANG Tianzi1,2, SONG Peng1,2, ZHANG Mingkai1,2, CHEN Mingfei1,2, LIU Yongxia1,2, YANG Qing1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China；2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-11-15 Published:2024-10-14

PDF (PC)

55

摘要： 坏疽性脓皮病是一种少见的嗜中性皮肤病，其发病机制目前尚不完全清楚，传统治疗包括系统应用糖皮质激素及环孢素、环磷酰胺等免疫抑制剂，但常规药物疗效并不十分令人满意。近年来，随着生物制剂在皮肤科领域的广泛应用，国外有越来越多超适应症应用生物制剂治疗坏疽性脓皮病的经验报道。现报道IL-17A抑制剂依奇珠单抗治疗坏疽性脓皮病一例，并对既往文献进行复习。

关键词: 坏疽性脓皮病, 依奇珠单抗, IL-17抑制剂

Abstract: Pyoderma gangrenosum is a rare neutrophilic dermatosis, its pathophysiology is not fully understood. Traditional treatments include systemic glucocorticoids and immunosuppressive therapies such as cyclosporine and cyclophosphamide, but their efficacy is often unsatisfactory. In recent years, there are more and more reports of off-label application of biological agents in the treatment of pyoderma gangrenosum in abroad. Herein, we report a case of pyoderma gangrenosum successfully treated with the IL-17A inhibitor ixekizumab and review the relevant literatures.

Key words: pyoderma gangrenosum, ixekizumab, IL-17 inhibitor